Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is expected to experience sustained growth and profits due to its strong product pipeline, direct-to-consumer sales, and potential in both developed and developing markets. Despite competitive pressures and regulatory challenges, the company has a successful track record and a customer-focused approach. With a neutral rating and positive price target from BTIG, MiniMed is a promising investment in the medical technology industry.

Bears say

Minimed Group is facing significant competition in the diabetes management market with many players focused on developing innovative products. Additionally, the uncertainty surrounding Medicare's competitive bidding program in 2028 could impact the company's revenue growth. Despite its strong international presence and leadership in multiple markets, about 60% of its revenue comes from just 10 countries, leaving it vulnerable to economic and regulatory changes in those regions. While the company has a strong portfolio of products and is investing in next-generation technologies, it faces challenges in expanding its market share in the highly competitive diabetes management industry.

MMED has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 10 analysts, MMED has a Buy consensus rating as of Jul 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.